debat shift execut
ex-u result less focu today fda approv
oab indic impli full-scal us launch begin
commerci execut key despit competit
dynam see axon drive share acceler
market pt
earli thought beyond axon report solid intern
result today number less relev debat axon receiv
r-snm approv oab indic us morn see note
scale us launch activ year-end focu
earn call manag bless consensu
revenu model slightli predic
share gain assum axon reach snm market share
base key devic advantag medtron interstim
oab fi-approv snm devic market
interstim recharg natur life full bodi mri
compat model next-gen interstim product
micro launch see month approv time
prudent estim follow pma file earli octob
market growth continu model global snm market compound-annual-growth-rate
market growth
product innov patient awar effort axon newli
launch websit social media page drive greater therapi adopt
addit comment earlier year impact dementia
concern ach inhibitor could snm therapi
get comfort trajectori expect revenu ramp
model total revenu us impli us implant
procedur weekli base asp view estim
achiev given axon alreadi engag top high-volum
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
implant us attend axon physician seminar
to-dat addit doctor attend last seminar decemb
off-set time need get committe procur
process doctor alon perform one rsnm procedur per
month would see revenu us upsid see
model prudent set project total sale ramp
respect expect axon
add us sale rep cours assum rep
across averag commerci forc devic averag mn rang
cash ampl near-term axon cash equival today
model equiti rais said acknowledg
import strong balanc sheet go larg
incumb expect manag remain opportunist
result earli us launch feedback axon report ex-u sale
versu estim higher oper expens
versu estim faster commerci ramp importantli call
commentari focus axon receipt r-snm approv oab
indic morn us launch updat axon announc
dozen implant procedur taken place us fi indic to-
date asp would impli compani track
us revenu within first week procedur see favor
rel estim us revenu given commerci
effort limit fi today dilig last weekend
boston physician seminar indic axon featur set includ size
longev recharg mri compatibl garner high level
interest among physician sens doctor intrigu
potenti therapeut advantag constant current deliveri moreov
simplic offer patient fewer devic control mechan
program
effect recently-fil ip lawsuit axon
creat mild nois field see sens recent seminar
manag approach concern transpar physician
less interest polit dynam rel valu proposit
axon featur set patient separ recent file pma
next-gen interstim micro see thought assum
month file launch allow reason window opportun
axon take share interim believ share captur end
launch believ market like acceler given
innov increas market potenti dementia risk driven
guidelin chang nuvectra signific compon market
model see chapter statu increment posit remain
remain overweight price discuss initi
axon uniqu opportun disrupt larg market
under-penetrated patient popul seen minim innov
decad see materi share gain market acceler creat
favor invest opportun rais price target reflect
ev/sal multipl revenu estim in-lin high-growth
smid-cap peer believ commerci execut drive multipl expans
take share expand sacral neuromodul snm market
take share expand sacral neuromodul snm market
price target base sale in-lin
stimul higher growth axon execut expect reach
market share within year creat strong inroad ahead next-gen
competit innov drive market growth near
take share grow market axon scale commerci
reach upper-teen market share within year
differenti product featur innov acceler snm market growth
mid-teen
meet resist axon less quarter make inroad
competit hit market axon market share top teen
axon appear pois materi
disrupt sacral neuromodul
snm market histor
domin given superior r-
snm product substanti smaller size
longer life recharg natur
vs current market lead devic
think axon take materi share
ahead competit respons expect
next-gen product compar
superior axon devic
better innov snm acceler
market growth mid-singl digit
mid-teen
fi oab approv
risk achiev price
current physician relationship could
sticki imagin make
difficult gain share
eventu slow share gain
market appetit high-growth pre-
impact multipl regardless
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
deferr rent net current portion
leas liabil net current portion
debt net unamort debt issuanc cost
accumul comprehens loss
dollar million except per share data
depreci amort
amort debt issuanc cost
chang oper asset liabil
prepaid expens current asset
purchas pp
chang short-term invest
payment debt issuanc cost
proce debt
proce issuanc prefer stock
payment prefer stock issuanc cost
proce common stock issuanc
proce exercis stock option
begin period
end period
